AJR Am J Roentgenol

1. ZHAO K, Yarmohammadi H
   Evidence Supporting the Shift Towards Radioembolization as the Primary Bridging Therapy for Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
   AJR Am J Roentgenol. 2026 Apr 15. doi: 10.2214/AJR.26.35001.
   

   >> Share

   
   

   
   Am J Gastroenterol

2. KAO KD, Troost JP, Yang JD, Salgia R, et al
   Patient Preferences in Hepatocellular Carcinoma Surveillance: A Multi-site Conjoint Analysis.
   Am J Gastroenterol. 2026 Apr 10. doi: 10.14309/ajg.0000000000004023.
   

   >> Share

   
   

   
   Ann Intern Med

3. ROGAL S
   Inpatient Management of Patients With Cirrhosis.
   Ann Intern Med. 2026 Apr 14. doi: 10.7326/ANNALS-26-00513.
   

   >> Share

   
   
4. ALAWADHI HK, Chang NH, Jogendran M, Bretthauer M, et al
   Gastroenterology/Hepatology: What You May Have Missed in 2025.
   Ann Intern Med. 2026 Apr 14:e2601058. doi: 10.7326/ANNALS-26-01058.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

5. LIN T, Weng N, Chen Y, Huang Z, et al
   Integrated transcriptomic analysis reveals a lncRNA-miRNA-TF-mRNA regulatory network underlying quercetin's anti-hepatocellular carcinoma effects.
   Biochem Biophys Res Commun. 2026;817:153651.
   

   >> Share

   
   
6. BAI L, Wang Y, Li G, Song Y, et al
   YEATS2/TAK1 axis mediates TGF-beta1 driven adaptive resistance to sorafenib in hepatocellular carcinoma.
   Biochem Biophys Res Commun. 2026;817:153693.
   

   >> Share

   
   
7. CHEN R, Liu H, Yang T, Jiang Z, et al
   3,3'-diindolylmethane ameliorates non-alcoholic fatty liver disease by inhibiting the FMO3-TMAO axis in mice.
   Biochem Biophys Res Commun. 2026;814:153641.
   

   >> Share

   
   

   
   BMC Cancer

8. LIU X, Li J, Yang C, Su Z, et al
   CK7-positive hepatocellular carcinoma represents a distinct subtype: a retrospective cohort study.
   BMC Cancer. 2026 Apr 14. doi: 10.1186/s12885-026-16001.
   

   >> Share

   
   
9. ZHANG Z, Lei P, Hu J, Wu J, et al
   Diagnostic performance and generalizability of preoperative prediction models for lymph node metastasis in intrahepatic cholangiocarcinoma: a multimodal evidence synthesis.
   BMC Cancer. 2026 Apr 17. doi: 10.1186/s12885-026-16024.
   

   >> Share

   
   

   
   BMC Gastroenterol

10. ABROKWA SK, Lenz J, Serfling L, Bielecke C, et al
    Idiopathic splenic vein stenosis with splenic infarction: a case report of rare non-bleeding cause of left-sided portal hypertension.
    BMC Gastroenterol. 2026;26:228.
    

    >> Share

    
    
11. TUFAEL D, Siddique AB, Rashid MHO, Mujahid MH, et al
    Vitamin D deficiency in chronic hepatitis B across the disease spectrum: association with viral activity rather than hepatocellular carcinoma.
    BMC Gastroenterol. 2026 Apr 11. doi: 10.1186/s12876-026-04808.
    

    >> Share

    
    
12. SHERIEF DE, Shehata HH, Nosair N, Othman AAA, et al
    Systemic hematologic, metabolic, and inflammatory dysregulation in liver cirrhosis and hepatocellular carcinoma: diagnostic utility of novel indices in an Egyptian cohort.
    BMC Gastroenterol. 2026;26:229.
    

    >> Share

    
    

    
    Br J Surg

13. WULLAERT L, van Leeuwen L, de Weerd V, Van M, et al
    Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naive colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort.
    Br J Surg. 2026;113:znaf295.
    

    >> Share

    
    

    
    Cancer Res

14. XU M, Gao X, Zhao J, Xu D, et al
    UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting beta-catenin-Driven Hybrid EMT and NK Cell Evasion.
    Cancer Res. 2026 Apr 17. doi: 10.1158/0008-5472.CAN-25-4755.
    

    >> Share

    
    

    
    Clin Res Hepatol Gastroenterol

15. WANG S, Lv J, Wang L, Cao X, et al
    Rising liver disease mortality in the United States, 1999-2023: Temporal trends and disparities.
    Clin Res Hepatol Gastroenterol. 2026;50:102791.
    

    >> Share

    
    
16. ONAY M, Heilani M, Gulia C, Matthias C, et al
    Sequential Anticoagulation with LMWH and DOACs in Cirrhotic Portal Vein Thrombosis.
    Clin Res Hepatol Gastroenterol. 2026 Feb 23:102792.
    

    >> Share

    
    
17. MERATI M, Shimano KA, Kim GE, Kambham N, et al
    Hematopoietic stem cell transplantation for erythropoietic porphyria-induced acute liver failure: a case report and literature review.
    Clin Res Hepatol Gastroenterol. 2026;50:102805.
    

    >> Share

    
    
18. XIAO Y, Li N, Jiang L, Wang H, et al
    Plasma EIF2C1 cell-free DNA as a novel biomarker for hepatocellular carcinoma diagnosis and risk stratification.
    Clin Res Hepatol Gastroenterol. 2026;50:102808.
    

    >> Share

    
    

    
    Endoscopy

19. MURABAYASHI T, Okuda H, Sugimoto S
    Troubleshooting of plastic stent impaction in the working channel during endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2026;58.
    

    >> Share

    
    

    
    Eur J Pediatr

20. CHOI S, Kim DU, Kim Y, Kim L, et al
    Native liver survival and genetic associations in Korean patients with Alagille syndrome.
    Eur J Pediatr. 2026;185:252.
    

    >> Share

    
    

    
    Eur Radiol

21. DOURNES G, Hadj Bouzid AI, Doucet K, Benlala I, et al
    Quantitative CT of emphysema, wall thickness and mucus plugs in alpha-1-antitrypsin deficiency: relationship to clinical outcomes.
    Eur Radiol. 2026;36:4098-4109.
    

    >> Share

    
    

    
    Hepatology

22. BAI DS, Dai Z, Zhou J, Liu YK, et al
    Retraction: Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma.
    Hepatology. 2026;83:E162.
    

    >> Share

    
    
23. LI B
    When the liver loses its zip code: Aging blurs zonation and breeds bi-zonal hepatocytes.
    Hepatology. 2026;83:1025-1026.
    

    >> Share

    
    
24. GU H, Arab JP
    Beyond clinical comorbidities: Social determinants of health shape cirrhosis risk.
    Hepatology. 2026;83:1027-1028.
    

    >> Share

    
    
25. SU JY, Li JR, Pan LX, Ma YL, et al
    Erratum: Tertiary lymphoid structures in hepatocellular carcinoma: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.
    Hepatology. 2026;83:E155-E157.
    

    >> Share

    
    
26. SUN Y, Wu C, Xin G, Zhong B, et al
    Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study.
    Hepatology. 2026;83:1248-1260.
    

    >> Share

    
    
27. YU X, Tian W, Bao X, Li Z, et al
    Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure.
    Hepatology. 2026;83:1174-1191.
    

    >> Share

    
    
28. CHUNG BK, Jordens MS, Ogaard J, Reims HM, et al
    Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001432.
    

    >> Share

    
    
29. IVANCOVSKY WAJCMAN D, Byrne CJ, Dillon JF, Brennan PN, et al
    A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;83:1303-1325.
    

    >> Share

    
    

    
    Indian J Gastroenterol

30. KUMAR A, Mukund A, Rudra O, Babbar S, et al
    Safety and efficacy of trans-jugular intrahepatic portosystemic shunt in patient with liver cirrhosis with hepatorenal syndrome non-acute kidney injury and refractory ascites-A retrospective analysis.
    Indian J Gastroenterol. 2026 Apr 13. doi: 10.1007/s12664-026-01977.
    

    >> Share

    
    

    
    J Comput Assist Tomogr

31. TAKAMATSU A, Yoneda N, Toshima F, Kitagawa T, et al
    A Preliminary Study of a Machine Learning Prediction of Poorly Differentiated Hepatocellular Carcinoma Based on a Comprehensive Parameter Analysis Using Dual-Energy Computed Tomography.
    J Comput Assist Tomogr. 2026 Apr 15. doi: 10.1097/RCT.0000000000001867.
    

    >> Share

    
    

    
    J Gastroenterol

32. SHI F, Peng Z, Lian S, Mai Q, et al
    Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort study.
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02406.
    

    >> Share

    
    

    
    J Gastroenterol Hepatol

33. GAO A, Luo J, Ye X, Hu Y, et al
    Comments on "Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort".
    J Gastroenterol Hepatol. 2026 Apr 17. doi: 10.1111/jgh.70395.
    

    >> Share

    
    
34. SIRAJ DS, Hollnagel F
    Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) and Risk of Hepatocellular Carcinoma (HCC) in Chronic Hepatitis B (CHB).
    J Gastroenterol Hepatol. 2026 Apr 16. doi: 10.1111/jgh.70398.
    

    >> Share

    
    

    
    J Hepatol

35. XU K, Dong X, Qu H, Hu J, et al
    AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC: Effect of the BA/Butyrate/CXCL14 axis in HCC.
    J Hepatol. 2026 Jan 21:S0168-8278(26)00016-4. doi: 10.1016/j.jhep.2025.
    

    >> Share

    
    
36. KRAG A, Tacke F, Israelsen M, Younossi ZM, et al
    Is liver steatosis a disease or the emperor's new clothes?
    J Hepatol. 2026;84:993-1001.
    

    >> Share

    
    
37. MURPHY N, El-Dalil P, Patel S, Ryan J, et al
    Use of intracranial pressure monitoring and risk factors for the development of intracranial hypertension in acute liver failure.
    J Hepatol. 2026;84:898-905.
    

    >> Share

    
    
38. ZHANG S, Xu H, Li M, Yuan G, et al
    An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC.
    J Hepatol. 2026;84:920-932.
    

    >> Share

    
    

    
    Lancet

39. GRAUPERA I, Thiele M, Castera L, Pera G, et al
    Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.
    Lancet. 2026;407:1448-1458.
    

    >> Share

    
    

    
    N Engl J Med

40. WANG S, Liu J, Xie F
    Hepatic Pseudoprogression after Treatment with Nectin-4-Targeted Antibody-Drug Conjugate.
    N Engl J Med. 2026;394:1548-1549.
    

    >> Share

    
    

    
    Oncogene

41. WANG F, Huang M, Sheng K, Yan Y, et al
    Dual inhibition of glycolysis and glutaminolysis by targeting FOXO3 for hepatocellular carcinoma treatment.
    Oncogene. 2026 Apr 13. doi: 10.1038/s41388-026-03765.
    

    >> Share

    
    
42. ZONG W, Cheng C, Zhang Y, Lu Y, et al
    GOT1 inhibits hepatocellular carcinoma progression by regulating SLC25A5-dependent mitochondrial apoptosis.
    Oncogene. 2026 Apr 14. doi: 10.1038/s41388-026-03769.
    

    >> Share

    
    

    
    PLoS One

43. SUZAKI N, Hayami S, Miyamoto A, Nakamura M, et al
    Impact of SETD8/KMT5A overexpression on hepatocellular carcinoma progression and prognosis.
    PLoS One. 2026;21:e0337503.
    

    >> Share

    
    
44. HONG C, Jiang L, Xia L
    Exploring the association between serum vitamins and CAP-defined hepatic steatosis in lean and non-lean adults with NAFLD: A cross-sectional study.
    PLoS One. 2026;21:e0346042.
    

    >> Share

    
    
45. JEON H, Kim SH, Shin D
    Examining the mediating effects of metabolic syndrome components on the relationship between dairy product consumption and nonalcoholic fatty liver disease in Korean adults.
    PLoS One. 2026;21:e0346774.
    

    >> Share

    
    

    
    Transplant Proc

46. BUDIMAN D, Chu CW, Oh J, Kang JH, et al
    Liver Transplantation Criteria for Hepatocellular Carcinoma: A Systematic Review.
    Transplant Proc. 2026 Apr 14:S0041-1345(26)00178.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share